BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway

INTRODUCTION: Gefitinib, well known as a new antitumor agent, has been applied in various cancers such as oral squamous cell carcinoma (OSCC). However, most patients eventually acquire resistance to gefitinib, and the molecular mechanism of gefitinib resistance is not well described. Bone marrow str...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Huang, Zhang, Lianping, Wang, Shufang, Qian, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Basic Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641506/
https://www.ncbi.nlm.nih.gov/pubmed/34900059
http://dx.doi.org/10.5114/aoms.2019.86183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641506/
https://www.ncbi.nlm.nih.gov/pubmed/34900059
http://dx.doi.org/10.5114/aoms.2019.86183

Ejemplares similares